Cellular Therapy of Leukemia
A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Pathology".
Deadline for manuscript submissions: 20 December 2024 | Viewed by 128
Special Issue Editor
Interests: clinical and translational research on MDS; MPN; leukemia; lymphoma; hematopoietic stem cell transplant/cellular therapy outcome research; bone marrow clonal malignant disease progression and leukemia transformation biomarkers and mechanisms
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Advances and development in immunotherapy methodology are significantly shifting the landscape of hematological malignant disease treatments. Allogeneic hematopoietic stem cell transplant, CAR-T therapy, and bispecific therapies demonstrate a track record of leukemia/lymphoma therapy methodology development towards more specific and effective treatment, with less toxicity and quality of life interference. Though we achieved a huge success in developing innovative methodologies for treating B cell-related leukemias/lymphomas, there is still an unmet need for myeloid lineage-related immunotherapy. This Special Issue will publish exciting research within this field and beyond.
Dr. Jeffrey Pu
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- immunotherapy
- leukemia
- lymphoma
- target therapy
- biomarker
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
